A small molecule p38α MAPK inhibitor, MW150, attenuates behavioral deficits and neuronal dysfunction in a mouse model of mixed amyloid and vascular pathologies

Background: Inhibition of p38 alpha mitogen activated protein kinase (p38α) has shown great promise as a treatment for Alzheimer's disease (AD) in preclinical tests. However, previous preclinical studies were performed in “pure” models of AD pathology. A vast majority of AD patients have comorbid de...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	Hilaree N. Frazier, David J. Braun, Caleb S. Bailey, Meggie J. Coleman, Verda A. Davis, Stephen R. Dundon, Christopher J. McLouth, Hana C. Muzyk, David K. Powell, Colin B. Rogers, Saktimayee M. Roy, Linda J. Van Eldik
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	Elsevier 2024-10-01
Cyfres:	Brain, Behavior, & Immunity - Health
Pynciau:	Alzheimer's disease VCID Hyperhomocysteinemia p38 MAPK Hippocampus neuroinflammation
Mynediad Ar-lein:	http://www.sciencedirect.com/science/article/pii/S2666354624001042
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!